Zobrazeno 1 - 10
of 214
pro vyhledávání: '"Direct Factor Xa inhibitor"'
Publikováno v:
Vascular Health and Risk Management, Vol Volume 20, Pp 231-244 (2024)
Soonil Kwon,1,* So-Ryoung Lee,2,3,* Eue-Keun Choi,2,3 Kyung-Yeon Lee,2 JungMin Choi,2 Hyo-Jeong Ahn,2 Seil Oh,2,3 Gregory Yoke Hong Lip2– 5 1Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea; 2Departm
Externí odkaz:
https://doaj.org/article/6525f9a53cc94f24a6190a0c97143fe7
Autor:
Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 4, Iss 1 (2024)
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor
Externí odkaz:
https://doaj.org/article/9afe5c2bf3dd4bf3923c253ead8387eb
Autor:
Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace, Craig I. Coleman
Publikováno v:
Critical Care, Vol 26, Iss 1, Pp 1-13 (2022)
Abstract Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. Four-factor proth
Externí odkaz:
https://doaj.org/article/5a95a8a8d12246ddbc13b48e098b4962
Autor:
Collaborators, Lorenz Meuli, Thomas Stadlbauer, Barbara E. Stähli, Christine Espinola-Klein, Alexander Zimmermann, on behalf of the PATENT Study Collaborators on behalf of the PATENT Study
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 9; Pages: 3223
(1) Background: High-level evidence on antithrombotic therapy after infrainguinal arterial bypass surgery in specific clinical scenarios is lacking. (2) Methods: A modified Delphi procedure was used to develop consensus statements. Experts voted on a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::a2b772cbf382000f4262620af2cdede2
Autor:
Kozue Ikeda, MD, Hideaki Tachibana, MD
Publikováno v:
Journal of Arrhythmia, Vol 32, Iss 1, Pp 42-50 (2016)
Background: Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine coagulation monitoring, high-risk patients require monitoring to assess pharmacodynamics. Methods: We measured (1) anti-factor Xa activit
Externí odkaz:
https://doaj.org/article/2165f69d2a494c0f9623b442d29bc025
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
John W. Eikelboom, Elena Zotova, Saskia Middeldorp, Andrew M. Demchuk, Pamela B. Conley, Tomoyuki Ohara, John T. Curnutte, Truman J. Milling, Mark Crowther, Stuart J. Connolly, Lizhen Xu, Peter Verhamme, Juliet Nakamya, Patrick Yue, Jose Lopez-Sendon, Joshua N. Goldstein
Publikováno v:
Stroke, 52(6), 2096-2105. Lippincott Williams and Wilkins
Stroke, 52, 6, pp. 2096-2105
Stroke, 52, 2096-2105
Stroke, 52, 6, pp. 2096-2105
Stroke, 52, 2096-2105
Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity with andexanet were assessed in patients from the AN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e2c937e778f22ef1b4cbdf304a8031
https://doi.org/10.1161/strokeaha.120.030565
https://doi.org/10.1161/strokeaha.120.030565
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Thrombosis Research, 184, 8-15. Elsevier Science
Thrombosis research, Vol. 184, p. 8-15 (2019)
Thrombosis research, Vol. 184, p. 8-15 (2019)
Background: Reliable assays to measure direct oral anticoagulant (DOAC) levels and their activity in critical situations are needed. Drug levels alone are not representative of the effect of DOACs on an individual's coagulation. We developed a techni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08d245986686dfca6f766e5df24e5dd4
https://doi.org/10.1016/j.thromres.2019.09.037
https://doi.org/10.1016/j.thromres.2019.09.037
Autor:
Lars Carl Borris
Publikováno v:
Vascular Health and Risk Management, Vol Volume 4, Pp 855-862 (2008)
Lars Carl BorrisDepartment of Orthopaedic Surgery, Åarhus University Hospital, Åarhus, DenmarkAbstract: Rivaroxaban (Xarelto®) is a member of a new class of oral, direct (antithrombin-independent) factor Xa inhibitors, which restrict thrombin gene
Externí odkaz:
https://doaj.org/article/38d13d1583e1455eb570885c52ec9d4f